New two-year data show 39 percent of NHL patients treated with CAR T remain in remission

(H. Lee Moffitt Cancer Center& Research Institute) A new article published today in The Lancet Oncology shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy (CAR T) Yescarta ® (axicabtagene ciloleucel) remained in remission more than two years (27.1 months median follow up) following therapy, and more than half of the patients treated remain alive.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news